Optimum duration of neoadjuvant letrozole to permit breast conserving surgery

Carpenter, R., Doughty, J. C., Cordiner, C., Moss, N., Gandhi, A., Wilson, C., Andrews, C., Ellis, G., Gui, G. and Skene, A. I. (2014) Optimum duration of neoadjuvant letrozole to permit breast conserving surgery. Breast Cancer Research and Treatment, 144(3), pp. 569-576. (doi: 10.1007/s10549-014-2835-8) (PMID:24562823)

Abstract

The aim of this multicenter, prospective, longitudinal phase IV study was to establish the optimal duration of neoadjuvant letrozole that would allow breast conservation surgery (BCS) in patients with early breast cancer who were initially unsuitable. Primary, invasive, estrogen-receptor- and/or progesterone-receptor-positive breast cancer patients, with large tumors (≥T2 i.e., >20 mm) not initially suitable for BCS, received 2.5 mg letrozole p.o. daily. Patients continued treatment until they became eligible for BCS, progressed, failed to meet criteria for BCS and withdrew for scheduled mastectomy, withdrew for other reasons, or completed 12 months of letrozole treatment without a BCS decision being made. A total of 146 patients were enrolled; seven patients who did not have a valid postbaseline tumor assessment were excluded from the final efficacy analysis. At study closure, 69 % of patients (96 of 139) were eligible for BCS. The median time to achieve a tumor response sufficient to allow BCS with neoadjuvant letrozole was 7.5 months (95 % CI 6.3–8.5 months). Letrozole was well tolerated, and most adverse events were mild-to-moderate (grade 1–2). The results from this trial suggest that extended letrozole therapy in the neoadjuvant setting (7.5 months), as opposed to conventional treatment of 4 months, is optimal to achieve maximum reduction in tumor volume sufficient for BCS.

• Item Type: Articles
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Doughty, Miss Julie
• Authors: Carpenter, R., Doughty, J. C., Cordiner, C., Moss, N., Gandhi, A., Wilson, C., Andrews, C., Ellis, G., Gui, G., and Skene, A. I.
• College/School: College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
• Journal Name: Breast Cancer Research and Treatment
• Publisher: Springer US
• ISSN: 0167-6806
• ISSN (Online): 1573-7217